Aficamten, a cardiac myosin inhibitor, was associated with improvements in symptom relief, diastolic function and parameters ...

Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – ...

This article is a report on the HR Tech 2026 in Las Vegas exhibition (EXPO).*Click here for last year's summary report! At HR ...

Beijer Electronics and its Vietnamese distribution partner, Air Vacuum Automation Vietnam Company Limited, signed a ...

Braveheart Bio (BRVE) looks undervalued in late-stage HCM with funded Phase 3 trials, strong cash runway and nHCM upside.

Specialty Program Group has acquired HCM Unlocked, expanding its employee benefits and workforce services platform with additional human capital management technology and managed services capabilities ...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Health Canada has issued ...

AstraZeneca (AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Good morning.Delivering today's Vietnam and international news.Online retail transaction value increased by 20%.The number of ...

Roundtable Conference in HCM City on October 23 focused on innovation, sustainable development and practical cooperation to ...

Among patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), treatment with aficamten resulted in significantly greater improvements in exercise capacity and quality of life ...